Our results indicate that in Eastern Morocco, hormone receptor-positive and HER2+ tumors are predominant and so the majority of breast cancer cases in this population may benefit from hormone therapy and/or targeted therapy. This evidence concerns the gene ERBB2 and breast cancer.